Clinical Chemistry Siemens Point of Care - Urinalysis
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 54: 86-92, 2008. First published November 2, 2007; 10.1373/clinchem.2007.092627
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2007.092627v1
54/1/86    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Söderlund-Strand, A.
Right arrow Articles by Carlson, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Söderlund-Strand, A.
Right arrow Articles by Carlson, J.
Related Collections
Right arrow Molecular Diagnostics and Genetics
(Clinical Chemistry. 2008;54:86-92.)
© 2008 American Association for Clinical Chemistry, Inc.

Molecular Diagnostics and Genetics

High-Throughput Genotyping of Oncogenic Human Papilloma Viruses with MALDI-TOF Mass Spectrometry

Anna Söderlund-Strand1,2, Joakim Dillner1,2 and Joyce Carlson3,a

1 WHO HPV LabNet Global Reference Laboratory and Departments of 2 Medical Microbiology and 3 Clinical Chemistry, Lund University, Malmö University Hospital, Malmö, Sweden.

aAddress correspondence to this author at: Department of Clinical Chemistry, Lund University, Malmö University Hospital, SE-205 02 Malmö, Sweden. Fax 46-40-336286; e-mail joyce.carlson{at}med.lu.se.

Background: Human papilloma virus (HPV) is the major cause of cervical cancer. Use of HPV genotyping in cervical screening programs and for monitoring the effectiveness of HPV vaccination programs requires access to economical, high-throughput technology.

Methods: We used the Sequenom MassARRAY platform to develop a high-throughput mass spectrometric (MS) method for detecting 14 specific oncogenic HPV genotypes in multiplex PCR products. We compared results from 532 cervical cell samples to the comparison method, reverse dot blot hybridization (RDBH).

Results: The MS method detected all samples found positive by RDBH. In addition, the MS method identified 5 cases of cervical disease (cervical intraepithelial neoplasia of grade I or higher) that RDBH analysis had missed. Discrepancies in specific genotypes were noted in 20 samples, all positive by MS, with an overall concordance of {kappa} = 0.945.

Conclusions: The MS high-throughput method, with a processing capacity of 10 x 384 samples within 2 working days and at a consumables cost of about US$2 per sample, performed as well as or better than the comparison method.




The following articles in journals at HighWire Press have cited this article:


Home page
 J. Clin. Microbiol.Home page
A. Soderlund-Strand, J. Carlson, and J. Dillner
Modified General Primer PCR System for Sensitive Detection of Multiple Types of Oncogenic Human Papillomavirus
J. Clin. Microbiol., March 1, 2009; 47(3): 541 - 546.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Association for Clinical Chemistry.